Trial · NCT01589237
Results by group120
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 120
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Patients With Any Adverse Events, Serious Adverse Events and Death | Placebo of Pradigastat (LCQ908) Regimen | At least one Adverse Event (any) | 11 | Participants | |
| Number of Patients With Any Adverse Events, Serious Adverse Events and Death | 20 mg Pradigastat (LCQ908) Regimen | At least one Adverse Event (any) | 12 | Participants | |
| Number of Patients With Any Adverse Events, Serious Adverse Events and Death | 40 mg Pradigastat (LCQ908) Regimen | At least one Adverse Event (any) | 10 | Participants | |
| Number of Patients With Any Adverse Events, Serious Adverse Events and Death | Pradigastat (LCQ908) Regimen- From Study A2212 | At least one Adverse Event (any) | 5 | Participants | |
| Number of Patients With Any Adverse Events, Serious Adverse Events and Death | Placebo of Pradigastat (LCQ908) Regimen | At least one serious AE | 1 | Participants | |
| Number of Patients With Any Adverse Events, Serious Adverse Events and Death | 20 mg Pradigastat (LCQ908) Regimen | At least one serious AE | 6 | Participants | |
| Number of Patients With Any Adverse Events, Serious Adverse Events and Death | 40 mg Pradigastat (LCQ908) Regimen | At least one serious AE | 2 | Participants | |
| Number of Patients With Any Adverse Events, Serious Adverse Events and Death | Pradigastat (LCQ908) Regimen- From Study A2212 | At least one serious AE | 2 | Participants | |
| Number of Patients With Any Adverse Events, Serious Adverse Events and Death | Placebo of Pradigastat (LCQ908) Regimen | Death | 0 | Participants | |
| Number of Patients With Any Adverse Events, Serious Adverse Events and Death | 20 mg Pradigastat (LCQ908) Regimen | Death | 0 | Participants | |
| Number of Patients With Any Adverse Events, Serious Adverse Events and Death | 40 mg Pradigastat (LCQ908) Regimen | Death | 0 | Participants | |
| Number of Patients With Any Adverse Events, Serious Adverse Events and Death | Pradigastat (LCQ908) Regimen- From Study A2212 | Death | 0 | Participants | |
| Changes From Baseline in Triglyceride Levels up to 52 Weeks | Placebo of Pradigastat (LCQ908) Regimen | Change in week 12 (n=10,11,10,5) | 1.63 | Geometric Coefficient of Variation 45.19 | percentage change |
| Changes From Baseline in Triglyceride Levels up to 52 Weeks | 20 mg Pradigastat (LCQ908) Regimen | Change in week 12 (n=10,11,10,5) | -5.80 | Geometric Coefficient of Variation 66.10 | percentage change |
| Changes From Baseline in Triglyceride Levels up to 52 Weeks | 40 mg Pradigastat (LCQ908) Regimen | Change in week 12 (n=10,11,10,5) | 43.94 | Geometric Coefficient of Variation 52.66 | percentage change |
| Changes From Baseline in Triglyceride Levels up to 52 Weeks | Pradigastat (LCQ908) Regimen- From Study A2212 | Change in week 12 (n=10,11,10,5) | -19.36 | Geometric Coefficient of Variation 42.82 | percentage change |
| Changes From Baseline in Triglyceride Levels up to 52 Weeks | Placebo of Pradigastat (LCQ908) Regimen | change in week 24 (n=10,10,9,5) | -14.59 | Geometric Coefficient of Variation 52.33 | percentage change |
| Changes From Baseline in Triglyceride Levels up to 52 Weeks | 20 mg Pradigastat (LCQ908) Regimen | change in week 24 (n=10,10,9,5) | -36.19 | Geometric Coefficient of Variation 64.80 | percentage change |
| Changes From Baseline in Triglyceride Levels up to 52 Weeks | 40 mg Pradigastat (LCQ908) Regimen | change in week 24 (n=10,10,9,5) | 32.54 | Geometric Coefficient of Variation 87.83 | percentage change |
| Changes From Baseline in Triglyceride Levels up to 52 Weeks | Pradigastat (LCQ908) Regimen- From Study A2212 | change in week 24 (n=10,10,9,5) | -26.05 | Geometric Coefficient of Variation 31.50 | percentage change |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01589237/results